{
    "clinical_study": {
        "@rank": "144725", 
        "arm_group": [
            {
                "arm_group_label": "1: Regimen A Escalation", 
                "arm_group_type": "Experimental", 
                "description": "1: OPB-111001, orally, once weekly"
            }, 
            {
                "arm_group_label": "2: Regimen A Extension", 
                "arm_group_type": "Experimental", 
                "description": "2: OPB-111001, orally, once weekly"
            }, 
            {
                "arm_group_label": "3: Regimen B Escalation", 
                "arm_group_type": "Experimental", 
                "description": "3: OPB-111001, orally, 2 - 3 times per week"
            }, 
            {
                "arm_group_label": "4: Regimen B Extension", 
                "arm_group_type": "Experimental", 
                "description": "4: OPB-111001, orally, 2 - 3 times per week"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the tolerability profile of OPB-111001 and to\n      determine the most suitable dose of OPB-111001 in patients with advanced cancer"
        }, 
        "brief_title": "A Clinical Trial to Determine the Most Suitable Dose of OPB-111001 in Patients With Advanced Cancer", 
        "condition": [
            "Prostate Cancer", 
            "Salivary Gland Cancer", 
            "Endometrial Cancer", 
            "Squamous Cell Carcinoma of the Cervix", 
            "Breast Cancer", 
            "Ovarian Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Breast Neoplasms", 
                "Carcinoma", 
                "Endometrial Neoplasms", 
                "Carcinoma, Squamous Cell", 
                "Ovarian Neoplasms", 
                "Prostatic Neoplasms", 
                "Salivary Gland Neoplasms", 
                "Uterine Cervical Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "---"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  \u2265 18 years of age\n\n          -  Patients with prostate cancer that is recurrent or did not respond to previous\n             hormone therapy and/or who have exhausted standard treatment options.\n\n        For the dose escalation parts only:\n\n        Patients who have exhausted standard treatment options with recurrent or refractory cancer\n        (ovarian cancer, cervical squamous cell carcinoma, breast cancer, salivary gland cancer,\n        endometrial cancer)\n\n          -  Histologically or cytologically documented diagnosis of cancer\n\n          -  Measurable disease according to RECIST Version 1.1 or for prostate cancer also\n             evaluable disease according to Prostate Cancer Working Group 2 (PCWG2) eligibility\n             criteria or for ovarian cancer also evaluable disease (non-measurable) according to\n             Gynaecologic Cancer Intergroup (GCIG) criteria\n\n          -  Absolute neutrophil count \u22651.5 (1500/mm3) and platelets \u2265100 \u00d7 109/L (without\n             platelet transfusion within the last 4 weeks before first study drug administration),\n             and haemoglobin \u22659 g/dL at Screening\n\n          -  Alanine aminotransferase and aspartate aminotransferase \u22642.5 \u00d7 the upper limit of\n             normal (ULN), Total bilirubin \u22641.5 \u00d7 ULN (exception: patients with liver metastasis\n             are allowed to have aspartate aminotransferase \u22645 \u00d7 ULN and alanine aminotransferase\n             \u22645 \u00d7 ULN) at screening\n\n          -  Albumin \u226526 g/L at Screening\n\n        Exclusion Criteria:\n\n          -  Concurrent prior treatment-related toxicity of Grade 2 or higher.  Exception: any\n             toxicity that is in the view of the investigator not a clinically significant safety\n             risk for Investigational medicinal product (IMP) administration.\n\n          -  Previous treatment with cytotoxic chemotherapy or other anticancer therapy within 4\n             weeks before the first dosing with study drug (at least 6 weeks for mitoxantrone,\n             nitrosurea, and bicalutamide).\n\n          -  Treatment with systemic glucocorticosteroids of more than a 2 mg dexamethasone\n             equivalent per day or in cases of treatment with \u22642 mg dexamethasone equivalent per\n             day:\n\n               1. Dosing was changed within 6 weeks before Screening or\n\n               2. The patient's cancer is responding to glucocorticosteroid intake\n\n          -  Radiation therapy within 4 weeks prior to the first dosing with IMP.\n\n          -  Treatment with a systemic IMP in a clinical trial within 28 days before the Screening\n             Visit.\n\n          -  Current or past history of clinically significant gastrointestinal disease or major\n             gastrointestinal surgery, malabsorption syndrome, or other conditions that could\n             interfere with enteral absorption.\n\n          -  Concurrent clinically significant unrelated systemic illness (e.g., serious\n             infection) or significant pulmonary, hepatic, or other organ dysfunction that would\n             compromise the patient's ability to tolerate study treatment or would likely\n             interfere with study procedures or results."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "79", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 17, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02042885", 
            "org_study_id": "314-12-401", 
            "secondary_id": "2013-001249-15"
        }, 
        "intervention": {
            "arm_group_label": [
                "1: Regimen A Escalation", 
                "2: Regimen A Extension", 
                "3: Regimen B Escalation", 
                "4: Regimen B Extension"
            ], 
            "description": "---", 
            "intervention_name": "OPB-111001", 
            "intervention_type": "Drug", 
            "other_name": "---"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "---", 
        "lastchanged_date": "April 4, 2014", 
        "location": [
            {
                "contact": {
                    "email": "sonia.serrano@icr.ac.uk", 
                    "last_name": "Sonia Serrano", 
                    "phone": "+44 (0) 208722 4087"
                }, 
                "facility": {
                    "address": {
                        "city": "London, Sutton", 
                        "country": "United Kingdom", 
                        "state": "Surrey", 
                        "zip": "SM2 5PT"
                    }, 
                    "name": "The Institute of Cancer Research, Royal Marsden NHS Foundation Trust"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "t.cole@imperial.ac.uk", 
                    "last_name": "Tom Cole, PhD", 
                    "phone": "+44 (0) 203 313 6198"
                }, 
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom", 
                        "zip": "W12 0HS"
                    }, 
                    "name": "NIHR/Wellcome Trust Imperial CRF/Imperial College Healthcare NHS Trust, Imperial Centre for Translational and Experimental Medicine (L-Block), Hammersmith Hospital"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Two-part Phase 1/2a, Open-label, Dose Escalation Study to Evaluate the Tolerability and Preliminary Antitumour Activity of OPB-111001 in Patients With Advanced Cancers That Are Poorly Responsive to Standard Anticancer Treatment", 
        "overall_contact": {
            "email": "clinicaltrial-314-12-401@otsuka.de", 
            "last_name": "Jutta Amersdorffer, Dr.", 
            "phone": "+49 (0) 89 2060205-00"
        }, 
        "overall_official": [
            {
                "affiliation": "The Institute of Cancer Research, Royal Marsden NHS Foundation Trust London United Kingdom", 
                "last_name": "Johann De Bono, Prof. Dr.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "NIHR/Wellcome Trust Imperial CRF, Imperial College Healthcare NHS Trust, Imperial Center for Translational and Experimental Medicine (L-Block), Hammersmith Hospital London, United Kingdom", 
                "last_name": "Sarah Blagden, Dr.", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "---", 
            "measure": "Maximum tolerated dose / Recommended Phase 2 dose; Tolerability", 
            "safety_issue": "Yes", 
            "time_frame": "after 2 or 6 weeks depending on study part; continously"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02042885"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Frequent sampling during Cycle 1 to 3, D1 only from Cycle 4 onwards", 
                "measure": "Pharmacokinetic parameters for OPB-111001 and its metabolites", 
                "safety_issue": "No", 
                "time_frame": "repeatedly until end of study (average of 3 months assumed)"
            }, 
            {
                "description": "--", 
                "measure": "Assessment of antitumor activity as defined by Response Evaluation Criteria in Solid Tumours (RECIST)", 
                "safety_issue": "No", 
                "time_frame": "repeatedly every 8th week until end of study (average of 3 months assumed)"
            }, 
            {
                "description": "---", 
                "measure": "Prostate-specific antigen (PSA) response in patients with prostate cancer", 
                "safety_issue": "No", 
                "time_frame": "repeatedly (Cycle 1 to 3 on Day 1, then every 4th week) until end of study (average of 3 months assumed)"
            }, 
            {
                "description": "---", 
                "measure": "Cancer antigen 125 (CA 125) response in patients with ovarian cancer", 
                "safety_issue": "No", 
                "time_frame": "repeatedly (Cycle 1 to 3 on Day 1, then every 4th week) until end of study (average of 3 months assumed)"
            }, 
            {
                "description": "---", 
                "measure": "Time to treatment failure", 
                "safety_issue": "No", 
                "time_frame": "At end of study (after average of 3 months assumed)"
            }
        ], 
        "source": "Otsuka Novel Products GmbH", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Otsuka Novel Products GmbH", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}